|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jiang H: Overview of gefitinib in
non-small cell lung cancer: An Asian perspective. Jpn J Clin Oncol.
39:137–150. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
NSCLC Meta-Analyses Collaborative Group, :
Chemotherapy in addition to supportive care improves survival in
advanced non-small-cell lung cancer: A systematic review and
meta-analysis of individual patient data from 16 randomized
controlled trials. J Clin Oncol. 26:4617–4625. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lara-Guerra H, Waddell TK, Salvarrey MA,
Joshua AM, Chung CT, Paul N, Boerner S, Sakurada A, Ludkovski O, Ma
C, et al: Phase II study of preoperative gefitinib in clinical
stage I non-small-cell lung cancer. J Clin Oncol. 27:6229–6236.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Roberts PJ, Stinchcombe TE, Der CJ and
Socinski MA: Personalized medicine in non-small-cell lung cancer:
Is KRAS a useful marker in selecting patients for epidermal growth
factor receptor-targeted therapy? J Clin Oncol. 28:4769–4777. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Isobe H, Gemma A, Harada M, Yoshizawa H, et
al: Gefitinib or chemotherapy for non-small-cell lung cancer with
mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pao W, Miller VA, Politi KA, Riely GJ,
Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of
lung adenocarcinomas to gefitinib or erlotinib is associated with a
second mutation in the EGFR kinase domain. PLoS Med. 2:e732015.
View Article : Google Scholar
|
|
8
|
Ciardicllo F and Tortora G: EGFR
antagonists in cancer treatment. N Engl J Med. 358:1160–1174. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Coorper WA, Lam DC, O'Toole SA and Minna
JD: Molecular biology of lung cancer. J Thorac Dis. 5 (Suppl
5):S479–S490. 2013.PubMed/NCBI
|
|
10
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gazdar AF: Activating and resistance
mutations of EGFR in non-small-cell lung cancer: Role in clinical
response to EGFR tyrosine kinase inhibitors. Oncology. 28 (Suppl
1):S24–S31. 2009.
|
|
13
|
Sharma SV, Bell DW, Settleman J and Haber
DA: Epidermal growth factor receptor mutations in lung cancer. Nat
Rev Cancer. 7:169–181. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chintala L and Kurzrock R: Epidermal
growth factor receptor mutation and diverse tumors: Case report and
concise literature review. Mol Oncol. 4:306–308. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Riely GJ, Pao W, Pham DK, Li AR, Rizvi N,
Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M and Miller VA:
Clinical course of patients with non-small cell lung cancer and
epidermal growth factor receptor exon 19 and exon 21 mutations
treated with gefitinib or erlotinib. Clin Cancer Res. 12:839–844.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC cancer staging manual. 7th. Chicago:
Springer; pp. 129–143. 2010
|
|
17
|
Taron M, Ichinose Y, Rosell R, Mok T,
Massuti B, Zamora L, Mate JL, Manegold C, Ono M, Queralt C, et al:
Activating mutations in the tyrosine kinase domain of the epidermal
growth factor receptor are associated with improved survival in
gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer
Res. 11:5878–5885. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Eisenhauer EA, Therasse P, Bogearts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sugio K, Uramoto H, Onitsuka T, Mizukami
M, Ichiki Y, Sugaya M, Yasuda M, Takenoyama M, Oyama T, Hanagiri T
and Yasumoto K: Prospective phase II study of gefitinib in
non-small cell lung cancer with epidermal growth factor receptor
gene mutations. Lung Cancer. 64:314–318. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schuler M, Yang JCH, Yamamoto N, O'Byrne
K, Hirsh V, Mok T, Massey D, Zazulina V, Shahidi M and Sequist L:
LUX-Lung 3: A randomized, open-label, phase III study of afatinib
versus pemetrexed and cisplatin as first-line treatment for
patients with advanced adenocarcinoma of the lung harboring
EGFR-activating mutations (Subgroup Analysis). Lung Cancer. 77
(Suppl 1):S25–S26. 2012. View Article : Google Scholar
|
|
21
|
Mok TS, Wu Y, Thongprasert S, Yang C, Chu
D, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N
Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor WJTOG3405): An open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou C, Wu Y, Chen G, Feng J, Liu X, Wang
C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang
Y, Li W, Hou M, Shi JH, Lee KY, et al: Afatinib versus cisplatin
plus gemcitabine for first-line treatment of Asian patients with
advanced non-small-cell lung cancer harbouring EGFR mutations
(LUX-Lung 6): An open-label, randomised phase 3 trial. Lancet
Oncol. 15:213–222. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu JY, Yu CJ, Yang CH, Wu SG, Chiu YH, Gow
CH, Chang YC, Hsu YC, Wei PF, Shih JY and Yang PC: First- or
second-line therapy with gefitinib produces equal survival in
non-small cell lung cancer. Am J Respir Crit Care Med. 178:847–853.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Massuti B, Morán T, Porta R, Queralt C,
Cardenal F, Mayo C, Camps C, Majem M, Tarón M and Rosell R:
Multicenter prospective trial of customized erlotinib for advanced
non-small cell lung cancer (NSCLC) patients (p) with epidermal
growth factor receptor (EGFR) mutations: Final results of the
Spanish lung cancer group (SLCG) trial. J Clin Oncol.
27:80232009.
|
|
28
|
Wang H, Huang J, Yu X, Han S, Yan X, Sun S
and Zhu X: Different efficacy of EGFR tyrosine kinase inhibitors
and prognosis in patients with subtypes of EGFR-mutated advanced
non-small cell lung cancer: A meta-analysis. J Cancer Res Clin
Oncol. 140:1901–1909. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jackman DM, Yeap BY, Sequist LV, Lindeman
N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS,
et al: Exon 19 deletion mutations of epidermal growth factor
receptor are associated with prolonged survival in non-small cell
lung cancer patients treated with gefitinib or erlotinib. Clin
Cancer Res. 12:3908–3914. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhu JQ, Zhong WZ, Zhang GC, Li R, Zhang
XC, Guo AL, Zhang YF, An SJ, Mok TS and Wu YL: Better survival with
EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small
cell lung cancer patients is due to differential inhibition of
downstream signals. Cancer Lett. 265:307–317. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sordella R, Bell DW, Haber DA and
Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer
activate anti-apoptotic pathways. Science. 305:1163–1167. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hata A, Yoshioka H, Fujita S, Kunimasa K,
Kaji R, Imai Y, Tomii K, Iwasaku M, Nishiyama A, Ishida T and
Katakami N: Complex mutations in the epidermal growth factor
receptor gene in non-small cell lung cancer. J Thorac Oncol.
5:1524–1528. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang Y, Li RQ, Ai YQ, Zhang J, Zhao PZ, Li
YF, He WJ, Xia YX and Li WH: Exon 19 deletion was associated with
better survival outcomes in advanced lung adenocarcinoma with
mutant EGFR treated with EGFR-TKIs as second-line therapy after
first-line chemotherapy: A retrospective analysis of 128 patients.
Clin Transl Oncol. 17:727–736. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Risbud MV, Fertala J, Vresilovic EJ,
Albert TJ and Shapiro IM: Nucleus pulposus cells upregulate
PI3K/Akt and MEK/ERK signaling pathways under hypoxic conditions
and resist apoptosis induced by serum withdrawal. Spine (Phila Pa
1976). 30:882–889. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bai H, Wang Z, Wang Y, Zhuo M, Zhou Q,
Duan J, Yang L, Wu M, An T, Zhao J and Wang J: Detection and
clinical significance of intratumoral EGFR mutational heterogeneity
in Chinese patients with advanced non-small cell lung cancer. PLoS
One. 8:e541702013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ke EE, Zhou Q, Zhang QY, Su J, Chen ZH,
Zhang XC, Xu CR, Yang JJ, Tu HY, Yan HH, et al: A higher proportion
of the EGFR T790M mutation may contribute to the better survival of
patients with exon 19 deletions compared with those with L858R. J
Thorac Oncol. 12:1368–1375. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tomonaga N, Nakamura Y, Yamaguchi H, Ikeda
T, Mizoguchi K, Motoshima K, Doi S, Nakatomi K, Iida T, Hayashi T,
et al: Analysis of intratumor heterogeneity of EGFR mutations in
mixed type lung adenocarcinoma. Clin Lung Cancer. 14:521–526. 2013.
View Article : Google Scholar : PubMed/NCBI
|
